Can-Fite BioPharma Ltd. (NYSE:CANF) Short Interest Update

Can-Fite BioPharma Ltd. (NYSE:CANF) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 102,500 shares, a drop of 42.7% from the August 31st total of 179,000 shares. Based on an average trading volume of 198,500 shares, the days-to-cover ratio is presently 0.5 days. Based on an average trading volume of 198,500 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers increased its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,268 shares of the company’s stock after buying an additional 11,388 shares during the period. Rhumbline Advisers owned 1.08% of Can-Fite BioPharma worth $57,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Trading Up 1.9%

Shares of Can-Fite BioPharma stock opened at $0.63 on Monday. The stock’s fifty day simple moving average is $0.66 and its 200 day simple moving average is $0.98. The company has a market capitalization of $2.24 million, a PE ratio of -0.35 and a beta of 1.01. Can-Fite BioPharma has a 12 month low of $0.59 and a 12 month high of $3.12.

Analysts Set New Price Targets

Separately, D. Boral Capital reissued a “buy” rating and set a $11.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, September 16th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $14.50.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.